Acute chest pain (ACP) is a common symptom that requires immediate attention due to its potential life-threatening implications. In modern healthcare, the management of ACP has significantly evolved, with an emphasis on prompt diagnosis and treatment to reduce morbidity and mortality.
The initial step in managing ACP involves a thorough history and physical examination, along with an electrocardiogram (ECG). The use of risk stratification tools, such as the HEART score, can aid in identifying high-risk patients who may benefit from immediate intervention.
Modern healthcare has witnessed the rise of novel biomarkers like High-Sensitivity Troponin (hs-cTn) which have improved the diagnostic accuracy of acute coronary syndrome (ACS). Additionally, advanced imaging modalities such as coronary CT angiography provide a non-invasive method for visualizing coronary artery disease.
The management of ACP includes both pharmacological and non-pharmacological strategies. Pharmacological interventions encompass nitrates, beta-blockers, and antiplatelet agents. Non-pharmacological interventions include lifestyle modifications and cardiac rehabilitation. In cases of ST-segment elevation myocardial infarction (STEMI), primary percutaneous coronary intervention (PCI) remains the treatment of choice.
The management of ACP is a multidisciplinary effort, involving cardiologists, emergency physicians, nurses, and pharmacists. The implementation of chest pain units (CPUs) in hospitals has shown to improve patient outcomes through rapid assessment and treatment.
In conclusion, the modern approach to managing ACP requires a combination of clinical assessment, risk stratification, advanced diagnostics, and prompt treatment strategies. A multidisciplinary team approach is crucial to ensure optimal patient care. As our understanding of ACP continues to evolve, it is essential for healthcare professionals to stay abreast of the latest guidelines and research in this field.
1.
Prostate cancer detection with PET CT and PET MRI is comparable.
2.
Refractory Multiple Myeloma Responsive to Immunotherapy Plus Low-Dose Radiotherapy
3.
AI Breath Test IDs Cancers; More Grief for Prior Auth; Imatinib Discoverer Resigns
4.
In NSCLC, subcutaneous Lazertinib + Amivantamab Dosing Is Not Worse Than IV Dosing.
5.
Loncastuximab-Rituximab Boosts Response Rates in R/R Follicular Lymphoma
1.
Innovative Intraoperative Therapies in Neurosurgical Oncology: Advancing Precision and Outcomes
2.
Unlocking the Potential of Bicalutamide 50 mg: A Revolutionary New Treatment for Prostate Cancer
3.
Holistic Oncology: Advancing Survivorship, Nursing, and Innovative Cancer Care Models
4.
Emerging Chemo-Immunotherapy: New Agents and Mechanisms in Modern Oncology
5.
The Dangers of Supratherapeutic INR: The Need for Increased Awareness and Monitoring
1.
Asian Symposium on Advancement in Hematology and Oncology
2.
Asian Symposium on Advancement in Hematology and Oncology
3.
Asian Symposium on Advancement in Hematology and Oncology
4.
International Cancer Conference
5.
Asian Symposium on Advancement in Hematology and Oncology
1.
Thromboprophylaxis In Medical Settings
2.
EGFR Mutation Positive Non-Small Cell Lung Cancer- Case Discussion & Conclusion
3.
Recent Data Analysis for First-Line Treatment of ALK+ NSCLC
4.
Efficient Management of First line ALK-rearranged NSCLC
5.
Post Progression Approaches After First-line Third-Generaion ALK Inhibitors
© Copyright 2026 Hidoc Dr. Inc.
Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation